论文部分内容阅读
目的 :探讨组胺 2受体拮抗剂西咪替丁 (CMD)在鼻咽癌综合治疗中的应用价值。方法 :6 5例无远处转移的鼻咽癌患者 ,随机分为两组。放射治疗组 ,放疗 DT:70～ 76 Gy/7～ 8周。放疗 +CMD组 ,放疗同上 ,CMD:16 0 0～ 2 0 0 0 mg,d1,分 4次口服 ,疗程为 4～ 6个月。结果 :5年生存率 ,放射治疗组为 5 9.38% (19/32 ) ,放射 +CMD组为 6 6 .6 7% (2 2 /33) ,P>0 .0 5。 5年无瘤生存率分别为 43.75 % (14/32 )和 6 3.6 4% (2 1/33) ,P>0 .0 5。 5年内复发和转移发生率 ,放射治疗组为 5 0 % (16 /32 ) ,放射 +CMD组为 2 4.2 4% (8/33) ,P<0 .0 5。差异有显著性。提示放射合并西咪替丁治疗可减少鼻咽癌的复发和转移。结论 :西咪替丁是一种经济、安全、有效的免疫调节剂 ,可能具有肿瘤治疗的应用价值。
Objective: To investigate the value of histamine 2 receptor antagonist cimetidine (CMD) in the comprehensive treatment of nasopharyngeal carcinoma. Methods: Totally 65 patients with nasopharyngeal carcinoma without distant metastasis were randomly divided into two groups. Radiotherapy group, radiotherapy DT: 70-76 Gy / 7-8 weeks. Radiotherapy + CMD group, radiotherapy as above, CMD: 1600 ~ 2000 mg, d1, 4 times orally for 4 to 6 months. Results: The 5-year survival rate was 59.38% (19/32) in radiotherapy group and 66.7% (2/33) in radiotherapy + CMD group, P> 0.05. The 5-year disease-free survival rates were 43.75% (14/32) and 6 3.6 4% (2 1/33) respectively, P> 0.05. The incidence of recurrence and metastasis within 5 years was 50% (16/32) in radiotherapy group and 4.224% (8/33) in radiotherapy + CMD group, P <0.05. The difference was significant. Prompt radiation cimetidine treatment can reduce the recurrence and metastasis of nasopharyngeal carcinoma. Conclusion: Cimetidine is an economical, safe and effective immunomodulator, which may have therapeutic value in cancer therapy.